SG11202113312VA - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist - Google Patents
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonistInfo
- Publication number
- SG11202113312VA SG11202113312VA SG11202113312VA SG11202113312VA SG11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA SG 11202113312V A SG11202113312V A SG 11202113312VA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonist
- administering
- methods
- specific immunotherapy
- treating allergy
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000013566 allergen Substances 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882992P | 2019-08-05 | 2019-08-05 | |
EP20315351 | 2020-07-16 | ||
PCT/US2020/044958 WO2021026203A1 (en) | 2019-08-05 | 2020-08-05 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113312VA true SG11202113312VA (en) | 2021-12-30 |
Family
ID=72088424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113312VA SG11202113312VA (en) | 2019-08-05 | 2020-08-05 | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Country Status (12)
Country | Link |
---|---|
US (2) | US11504426B2 (zh) |
EP (1) | EP4010001A1 (zh) |
JP (1) | JP2022543815A (zh) |
KR (1) | KR20220042217A (zh) |
CN (1) | CN114173819A (zh) |
AU (1) | AU2020325021A1 (zh) |
BR (1) | BR112022000581A2 (zh) |
CA (1) | CA3147068A1 (zh) |
IL (1) | IL289613B2 (zh) |
MX (1) | MX2022001030A (zh) |
SG (1) | SG11202113312VA (zh) |
WO (1) | WO2021026203A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
JP2019531273A (ja) | 2016-09-01 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
CA2108886A1 (en) | 1991-05-03 | 1992-11-04 | Thasia G. Woodworth | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
ZA946875B (en) | 1993-09-07 | 1995-07-06 | Smithkline Beecham Corp | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
DE69931377T2 (de) | 1998-09-18 | 2007-05-10 | Dynavax Technologies Corp., Berkeley | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
DE60130466T2 (de) | 2000-07-26 | 2008-06-12 | Hououdou Co. Ltd. | Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
CN1507353A (zh) | 2001-05-11 | 2004-06-23 | ��˹��ŵ�� | 用于治疗IgE相关性疾病的组合物 |
US20050074462A1 (en) | 2001-05-23 | 2005-04-07 | Duotol Ab | Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof |
DK1461300T3 (da) | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
ATE435239T1 (de) | 2002-03-29 | 2009-07-15 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
WO2004047793A1 (en) | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
ES2575547T3 (es) | 2003-02-01 | 2016-06-29 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
WO2005063817A2 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il−4/il−13特異的ポリペプチドおよびその治療上の使用 |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
RU2445318C2 (ru) | 2006-10-02 | 2012-03-20 | Ридженерон Фармасьютикалз, Инк. | Высокоаффинные антитела человека к рецептору il-4 человека |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
RS53402B (en) | 2007-03-22 | 2014-10-31 | Genentech, Inc. | APPLICATION OF APOPTOTIC ANTI-IGE ANTIBODIES FOR MEMBRANE IGE |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
US20110301046A1 (en) | 2008-12-01 | 2011-12-08 | Children's Hospital Medical Center | Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis |
WO2010120511A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Method of treating respiratory disorders |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
CN107320722A (zh) | 2009-09-07 | 2017-11-07 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
EP3970726A1 (en) | 2010-06-24 | 2022-03-23 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
KR101867279B1 (ko) | 2010-10-06 | 2018-06-15 | 리제너론 파아마슈티컬스, 인크. | 항―인터류킨―4 수용체(il-4r) 항체를 함유하는 안정화된 제형 |
RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
WO2012094643A2 (en) | 2011-01-06 | 2012-07-12 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
EP2723899B1 (en) | 2011-06-21 | 2020-11-18 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
EP2763683A1 (en) | 2011-10-06 | 2014-08-13 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
MX2014009043A (es) | 2012-01-31 | 2014-10-14 | Genentech Inc | Anticuerpos anti-ige y sus metodos de uso. |
WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
CN110624107A (zh) | 2012-08-21 | 2019-12-31 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
PL3010539T3 (pl) | 2013-06-21 | 2020-01-31 | Sanofi Biotechnology | Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
CA2940295A1 (en) | 2014-02-21 | 2015-08-27 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
KR20170081262A (ko) | 2014-11-14 | 2017-07-11 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
JP2019505554A (ja) | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
JP2019531273A (ja) | 2016-09-01 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 |
JP7164530B2 (ja) | 2016-09-22 | 2022-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
JP2022543612A (ja) | 2019-08-05 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 |
IL293487A (en) | 2019-12-09 | 2022-08-01 | Sanofi Biotechnology | Methods for the treatment of digitally identified il-4/il-13-related disorders |
IL298257A (en) | 2020-05-22 | 2023-01-01 | Regeneron Pharma | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
-
2020
- 2020-08-05 US US16/985,665 patent/US11504426B2/en active Active
- 2020-08-05 CA CA3147068A patent/CA3147068A1/en active Pending
- 2020-08-05 MX MX2022001030A patent/MX2022001030A/es unknown
- 2020-08-05 AU AU2020325021A patent/AU2020325021A1/en active Pending
- 2020-08-05 BR BR112022000581A patent/BR112022000581A2/pt unknown
- 2020-08-05 CN CN202080055380.2A patent/CN114173819A/zh active Pending
- 2020-08-05 KR KR1020227007521A patent/KR20220042217A/ko active Search and Examination
- 2020-08-05 JP JP2022507353A patent/JP2022543815A/ja active Pending
- 2020-08-05 EP EP20757494.8A patent/EP4010001A1/en active Pending
- 2020-08-05 WO PCT/US2020/044958 patent/WO2021026203A1/en unknown
- 2020-08-05 SG SG11202113312VA patent/SG11202113312VA/en unknown
- 2020-08-05 IL IL289613A patent/IL289613B2/en unknown
-
2022
- 2022-10-19 US US18/047,972 patent/US20230293682A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022001030A (es) | 2022-04-26 |
US11504426B2 (en) | 2022-11-22 |
IL289613B2 (en) | 2023-09-01 |
CA3147068A1 (en) | 2021-02-11 |
IL289613A (en) | 2022-03-01 |
EP4010001A1 (en) | 2022-06-15 |
CN114173819A (zh) | 2022-03-11 |
IL289613B1 (en) | 2023-05-01 |
JP2022543815A (ja) | 2022-10-14 |
US20210038715A1 (en) | 2021-02-11 |
AU2020325021A1 (en) | 2022-01-06 |
BR112022000581A2 (pt) | 2022-03-03 |
KR20220042217A (ko) | 2022-04-04 |
US20230293682A1 (en) | 2023-09-21 |
WO2021026203A1 (en) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202113312VA (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist | |
IL273678A (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an il-4r inhibitor | |
IL274134A (en) | Methods of treating or preventing asthma by administering an IL-4R agonist | |
ZA202004919B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
SG11202100972WA (en) | Block chain-based claim settlement method and apparatus | |
IL269593A (en) | Anti-ILT4 antibodies and antigen-binding fragments | |
IL259847A (en) | Bispecific antigen binding proteins against tl1a and tnf-alpha and their uses | |
PT3107575T (pt) | Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r | |
IL269074A (en) | Proteins that bind anti-TIGIT antigens and methods of using them | |
PH12016500940A1 (en) | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE | |
IL304240A (en) | Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist | |
ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
IL278812A (en) | Peptides and methods for detecting peanut allergies | |
HK1251582A1 (zh) | 人源化的抗-tau(ps422)抗體和使用方法 | |
IL281769A (en) | CD40L antagonist and uses thereof | |
IL292198A (en) | Tim-3 inhibitors and their uses | |
SG10202011023YA (en) | Dna monoclonal antibodies targeting il-6 and cd126 | |
IL294066A (en) | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist | |
IL289731A (en) | Methods for treating or preventing asthma by administering an antagonist to il-4r | |
SG11201912786WA (en) | Block Chain-based File Protection Method and Terminal Device | |
IL292238A (en) | Sequences of clec12a antibody fragments and methods | |
SG11202004154SA (en) | Aptamer for adamts5 and use for aptamer for adamts5 | |
PT3703818T (pt) | Antagonista de il-4r para utilização num método para o tratamento ou prevenção de asma | |
EP3705172A4 (en) | DEVICE AND METHOD FOR REMOVING ACID GASES |